Europe says 'hello Dolly' to the biotech directive

  • Binns R
  • Driscoll B
  • 5

    Readers

    Mendeley users who have this article in their library.
  • 2

    Citations

    Citations of this article.

Abstract

Nearly a decade after it was first proposed, the European Biotechnology Directive has finally been passed into law. The main purpose of the Directive is to provide a uniform set of legal rules that will apply to biotechnology patents throughout the 15 countries of the European Union. The authors describe how the Directive confirms that, subject to meeting the normal criteria, patents can be granted for inventions involving DNA, cell lines, microorganisms, plants, animals and human-derived material. However, on moral grounds, patents will not be allowed for certain inventions involving human cloning, germ-line gene therapy, human embryos or transgenic animals.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Richard Binns

  • Bryan Driscoll

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free